

**Table S6** – Furosemide dose (mg/kg) and dose adjustments in the FAS population (n=76)

	Group	Treatment	N	Mean ± SD	Median	Min	Max
D0	All	Pimobendan	39	3.4 ± 1.92	2.8	0.6	8.1
		Placebo	37	3.6 ± 1.98	3.2	0.6	7.0
	LVOTO	Pimobendan	14	3.6 ± 1.43	3.6	1.4	5.8
		Placebo	15	4.5 ± 2.01	4.0	1.3	7.0
	No LVOTO	Pimobendan	25	3.3 ± 2.16	2.5	0.6	8.1
		Placebo	22	3.0 ± 1.71	2.5	0.6	6.5
Average dose over study period	All	Pimobendan	39	3.7 ± 2.82	3.2	0.0	9.5
		Placebo	37	4.1 ± 2.34	4.1	0.6	9.6
	LVOTO	Pimobendan	14	3.5 ± 2.40	3.6	0.0	7.1
		Placebo	15	4.8 ± 2.41	4.5	1.0	9.6
	No LVOTO	Pimobendan	25	3.8 ± 3.07	2.3	0.5	9.5
		Placebo	22	3.7 ± 2.24	3.4	0.6	8.5
Time adjusted AUC of dose as difference to baseline	All	Pimobendan	28	0.6 ± 1.85	0.3	-4.3	4.5
		Placebo	30	0.7 ± 1.29	0.6	-2.5	3.4
	LVOTO	Pimobendan	9	0.4 ± 2.29	0.4	-4.3	4.2
		Placebo	12	0.3 ± 1.60	0.3	-2.5	3.4
	No LVOTO	Pimobendan	19	0.7 ± 1.67	0.2	-1.6	4.5
		Placebo	18	0.9 ± 1.03	0.9	-0.9	2.7

*Notes:* There were no differences of furosemide between treatments for all groups ( $P > .05$ ).

Abbreviations: FAS, full analysis set population; LVOTO, left ventricular outflow tract obstruction; D0, day of first administration of medication; AUC, area under the curve.